Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021

Rhea-AI Summary

Compugen Ltd. (Nasdaq: CGEN) announces it will release its second quarter 2021 financial results on July 28, 2021, before U.S. markets open. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. The call can be accessed via telephone or through a live webcast on the company's website. Compugen is focused on cancer immunotherapy with key products like COM701 and COM902 undergoing clinical studies.

Positive

• Upcoming release of second quarter 2021 financial results could provide valuable insights for investors.
• Management will host a call to discuss results, potentially offering transparency and updates on corporate strategy.

Negative

• None.

HOLON, Israel, July 14, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2021 financial results on Wednesday, July 28, 2021 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located at the following link

Following the live audio webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 single, dual and triple combination studies. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. Compugen's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com

Investor Relations contact:
Yvonne Naughton, PhD
Head of Investor Relations and Corporate Communications Compugen Ltd.
Email: ir@cgen.com
Tel: +1 (628) 241-0071

 

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2021-results-on-wednesday-july-28-2021-301333441.html

SOURCE Compugen Ltd.

FAQ

When will Compugen release its second quarter 2021 financial results?

Compugen will release its second quarter 2021 financial results on July 28, 2021.

What time is the conference call for Compugen's Q2 2021 results?

The conference call for Compugen's Q2 2021 results is scheduled for 8:30 AM ET.

How can I access the webcast for Compugen's Q2 2021 financial results?

The webcast can be accessed through Compugen's corporate website.

What are Compugen's key products in clinical studies?

Compugen's key products in clinical studies include COM701 and COM902.

What is Compugen's stock symbol?

Compugen is listed on Nasdaq under the ticker symbol CGEN.